Please Wait.....
Report
Germany Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032
Market Report I 2024-06-17 I 138 Pages I Inkwood Research
KEY FINDINGS
The Germany RNA interference (RNAi) drug delivery market is approximated to grow at a CAGR of 22.94% over the forecast period of 2024-2032. It is set to reach a revenue of $23164.24 million by 2032.
MARKET INSIGHTS
The Germany RNA interference (RNAi) drug delivery market is experiencing significant growth, driven by the increasing demand for RNAi therapeutics. This surge in demand is fueled by the promising potential of RNAi technologies in treating various diseases, offering a novel approach that targets the root cause at the genetic level. As research and development in RNA-based therapies continue to advance, the market is expected to see substantial growth. This growth reflects the broader global trend towards personalized and precision medicine.
In Germany, the rising prevalence of chronic diseases is further boosting the demand for RNAi drug delivery solutions. Conditions such as cancer, cardiovascular diseases, and neurological disorders are becoming more common, necessitating innovative treatment approaches. RNAi therapeutics offer a promising solution by effectively silencing specific genes involved in disease progression. This targeted approach enhances the efficacy of treatments and minimizes side effects, making it a preferable option in the management of chronic diseases.
Among the various applications of RNAi drug delivery, cardiology stands out as the fastest-growing segment. The application of RNAi in cardiology focuses on addressing genetic factors contributing to heart diseases, offering new hope for patients with conditions that are difficult to treat with conventional therapies. The ability of RNAi to precisely target and regulate specific genes involved in cardiovascular diseases makes it a transformative approach. This capability drives its rapid adoption and growth within this medical field.
Nanoparticle drug delivery technology is predominantly preferred for RNAi therapeutics due to its efficiency in delivering RNA molecules to target cells. Nanoparticles protect RNA molecules from degradation and enhance their delivery to the desired site of action within the body. This technology ensures that the therapeutic RNA reaches its target efficiently, improving the overall effectiveness of the treatment. The adoption of nanoparticle drug delivery systems is a major factor propelling the growth of the market in Germany. This aligns with the increasing emphasis on precision and efficacy in modern medical treatments.
SEGMENTATION ANALYSIS
The Germany RNA interference (RNAi) drug delivery market segmentation incorporates the market by application and technology. The application segment is further bifurcated into oncology, infectious disease, neurology, cardiology, metabolic disorders, ophthalmology, urology, and other applications. Oncology is a prominent sub-segment within the market in Germany. RNAi therapeutics have shown considerable promise in targeting and silencing specific genes responsible for cancer progression. By inhibiting these genes, RNAi can effectively reduce tumor growth and enhance the efficacy of existing treatments. This approach offers new avenues for cancer treatment and holds the potential to overcome resistance to conventional therapies. As a result, it has become a critical area of focus in the ongoing fight against cancer.
Neurology is another key sub-segment where RNAi technologies are making significant strides. Neurological disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, often involve complex genetic components that are difficult to treat with traditional methods. RNAi offers a novel approach by targeting these genetic factors directly, potentially altering the course of these debilitating conditions. The ability to precisely regulate gene expression in the nervous system opens up new possibilities for managing and treating neurological diseases, driving the growth of RNAi applications in this field.
Ophthalmology also benefits from RNAi drug delivery systems, particularly in the treatment of diseases like macular degeneration and glaucoma. These conditions often result from genetic mutations or abnormal gene expressions that can be effectively targeted by RNAi therapeutics. By silencing the problematic genes, RNAi can help preserve vision and improve the quality of life for patients suffering from these eye diseases. The precision and specificity of RNAi make it an attractive option for ophthalmological applications, further expanding its market potential.
COMPETITIVE ANALYSIS
Top players operating in the Germany RNA interference (RNAi) drug delivery market include Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Ionis Pharmaceuticals Inc, etc.
Alnylam Pharmaceuticals Inc, headquartered in the United States, is a global biopharmaceutical company specializing in RNAi-based therapeutics. With five approved RNAi drugs, Alnylam targets genetically validated genes linked to human diseases. The company's strategy focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Utilizing N-acetylgalactosamine (GalNAc) conjugates and lipid nanoparticles (LNP) for drug delivery, Alnylam effectively administers treatments, including the use of hexadecyl (C16) for ocular and CNS delivery.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.6. MAJOR MARKET FINDINGS
2.6.1. CARDIOLOGY IS THE FASTEST-GROWING RNAI DRUG DELIVERY APPLICATION
2.6.2. NANOPARTICLE DRUG DELIVERY IS THE MAJORLY PREFERRED RNAI DRUG DELIVERY TECHNOLOGY
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING DEMAND FOR RNA-BASED THERAPEUTICS TO STIMULATE MARKET GROWTH
3.1.2. RISING PREVALENCE OF CHRONIC DISEASES FOSTERS MARKET DEMAND
3.1.3. GROWING INVESTMENT IN RNA-BASED RESEARCH TO ESCALATE THE MARKET GROWTH
3.2. KEY RESTRAINTS
3.2.1. THE COMPLEXITY OF RNAI TECHNOLOGY IS PREDICTED TO HINDER MARKET DEMAND
3.2.2. REGULATORY CHALLENGES ARE EXPECTED TO FURTHER COMPLICATE MARKET GROWTH
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RNAI DRUGS HAVE APPLICATIONS IN CANCER TREATMENT
4.1.2. INFECTIOUS DISEASES ARE LEADING TO INCREASED TRACTION IN RNAI DRUGS
4.1.3. VENTURE FUNDING FOR RNAI DRUGS HAS INCREASED SUBSTANTIALLY
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR GERMANY
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. PRIMARY ACTIVITIES
4.6.1.1. RESEARCH AND DEVELOPMENT (R&D)
4.6.1.2. MANUFACTURING
4.6.1.3. LOGISTICS AND DISTRIBUTION
4.6.1.4. MARKETING AND SALES
4.6.1.5. AFTER-SALES SERVICE
4.6.2. SUPPORT ACTIVITIES
4.6.2.1. PROCUREMENT
4.6.2.2. TECHNOLOGY DEVELOPMENT
4.6.2.3. HUMAN RESOURCE MANAGEMENT
4.6.2.4. FIRM INFRASTRUCTURE
4.6.2.5. REGULATORY AFFAIRS AND COMPLIANCE
4.7. KEY BUYING CRITERIA
4.7.1. EFFICACY AND SAFETY
4.7.2. MECHANISM OF ACTION AND TARGET SPECIFICITY
4.7.3. DELIVERY SYSTEM AND ADMINISTRATION ROUTE
4.7.4. COMPETITIVE ADVANTAGE AND DIFFERENTIATION
4.7.5. REGULATORY APPROVAL AND COMPLIANCE
4.7.6. COST AND REIMBURSEMENT
4.7.7. INTELLECTUAL PROPERTY AND EXCLUSIVITY
4.7.8. MANUFACTURING CAPABILITIES AND SUPPLY CHAIN
4.7.9. COMPANY REPUTATION AND EXPERIENCE
5. MARKET BY APPLICATION
5.1. ONCOLOGY
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. INFECTIOUS DISEASE
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. NEUROLOGY
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
5.4. CARDIOLOGY
5.4.1. MARKET FORECAST FIGURE
5.4.2. SEGMENT ANALYSIS
5.5. METABOLIC DISORDERS
5.5.1. MARKET FORECAST FIGURE
5.5.2. SEGMENT ANALYSIS
5.6. OPHTHALMOLOGY
5.6.1. MARKET FORECAST FIGURE
5.6.2. SEGMENT ANALYSIS
5.7. UROLOGY
5.7.1. MARKET FORECAST FIGURE
5.7.2. SEGMENT ANALYSIS
5.8. OTHER APPLICATIONS
5.8.1. MARKET FORECAST FIGURE
5.8.2. SEGMENT ANALYSIS
6. MARKET BY TECHNOLOGY
6.1. NANOPARTICLE DRUG DELIVERY
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. PULMONARY DRUG DELIVERY
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. NUCLEIC ACID DRUG DELIVERY
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
6.4. APTAMER DRUG DELIVERY
6.4.1. MARKET FORECAST FIGURE
6.4.2. SEGMENT ANALYSIS
7. COMPETITIVE LANDSCAPE
7.1. KEY MARKET STRATEGIES
7.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.2. PARTNERSHIPS & AGREEMENTS
7.2. COMPANY PROFILES
7.2.1. ALNYLAM PHARMACEUTICALS INC
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCT PORTFOLIO
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. ARBUTUS BIOPHARMA CORP
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCT PORTFOLIO
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. ARCTURUS THERAPEUTICS INC
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCT PORTFOLIO
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. ARROWHEAD PHARMACEUTICALS INC
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCT PORTFOLIO
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. IONIS PHARMACEUTICALS INC
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCT PORTFOLIO
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. SILENCE THERAPEUTICS PLC
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCT PORTFOLIO
7.2.6.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - RNA INTERFERENCE (RNAI) DRUG DELIVERY
TABLE 2: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 7: LIST OF PARTNERSHIPS & AGREEMENTS
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR GERMANY
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
FIGURE 9: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY ONCOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 10: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY INFECTIOUS DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 11: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NEUROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY CARDIOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 13: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY METABOLIC DISORDERS, 2024-2032 (IN $ MILLION)
FIGURE 14: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OPHTHALMOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 15: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 16: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2024-2032 (IN $ MILLION)
FIGURE 17: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2023
FIGURE 18: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NANOPARTICLE DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 19: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY PULMONARY DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 20: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY NUCLEIC ACID DRUG DELIVERY, 2024-2032 (IN $ MILLION)
FIGURE 21: GERMANY RNA INTERFERENCE (RNAI) DRUG DELIVERY MARKET, BY APTAMER DRUG DELIVERY, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security